The metabolic mechanisms specifically responsible for semaglutide-improved stroke recovery are hard to pinpoint because it is essentially impossible to separate the effects of any treatment targeting body weight without also affecting glucose and insulin sensitivity. The gene discussed is INS; the disease is stroke disorder.